Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; William Harvey Research Institute, NIHR Barts Biomedical Centre, Queen Mary University London, UK.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; William Harvey Research Institute, NIHR Barts Biomedical Centre, Queen Mary University London, UK; University of Pennsylvania, Pennsylvania, USA; Center for Inherited Cardiovascular Disease, WellSpan Health, Lancaster, PA, USA.
Mayo Clin Proc. 2024 Mar;99(3):362-374. doi: 10.1016/j.mayocp.2023.09.009. Epub 2024 Feb 6.
To contemporaneously reappraise the incidence-rate, prevalence, and natural history of hypertrophic cardiomyopathy (HCM) in Olmsted County, Minnesota, from 1984 to 2015.
A validated medical-record linkage system collecting information for residents of Olmsted County was used to identify all cases of HCM between January 1, 1984, and December 31, 2015. After adjudication of records from Mayo Clinic and Olmsted Medical Center, data relating to diagnoses and outcomes were abstracted. The calculated incidence rate and prevalence were standardized to the US 1980 White population (age- and sex-adjusted) and compared with a prior study examining the years 1975-1984.
Two hundred seventy subjects with HCM were identified. The age- and sex-adjusted incidence rate was 6.6 per 100,000 person-years, and the point prevalence of HCM on January 1, 2016, was 89 per 100,000 population. The incidence rate and point prevalence of HCM on January 1, 2016, standardized to the US 1980 White population (age- and sex-adjusted), were 6.7 (95% CI, 7.1 to 8.8) per 100,000 person-years and 81.5 per 100,000 population, respectively. The incidence rate of HCM increased each decade since the index study. Individuals with HCM had a higher overall standardized mortality rate than the general population with an observed to expected HR of 1.44 (95% CI, 1.21 to 1.71; P<.001) which improved by each decade.
The incidence and prevalence of HCM are higher than rates reported from a prior study in the same community examining the years 1975-1984, but lower than other study cohorts. The risk of mortality in HCM remains higher than expected, albeit with improvement in rates of mortality observed each decade during the study period.
重新评估明尼苏达州奥姆斯特德县从 1984 年到 2015 年肥厚型心肌病（HCM）的发病率、患病率和自然病史。
使用经过验证的病历链接系统收集奥姆斯特德县居民的信息，以确定 1984 年 1 月 1 日至 2015 年 12 月 31 日期间所有 HCM 病例。在对梅奥诊所和奥姆斯特德医疗中心的记录进行裁决后，提取与诊断和结果相关的数据。计算出的发病率和患病率按美国 1980 年白人人口（年龄和性别调整）进行标准化，并与之前研究 1975-1984 年的结果进行比较。
共确定了 270 例 HCM 患者。年龄和性别调整后的发病率为每 100000 人年 6.6 例，2016 年 1 月 1 日的 HCM 点患病率为每 100000 人 89 例。按美国 1980 年白人人口（年龄和性别调整）标准化后的 2016 年 1 月 1 日的 HCM 发病率和点患病率分别为每 100000 人年 6.7（95%CI，7.1 至 8.8）和每 100000 人 81.5。自本研究开始以来，HCM 的发病率每十年增加一次。与普通人群相比，HCM 患者的整体标准化死亡率更高，观察到的预期 HR 为 1.44（95%CI，1.21 至 1.71；P<.001），每十年有所改善。
HCM 的发病率和患病率高于同一社区之前研究报告的 1975-1984 年的发病率和患病率，但低于其他研究队列。尽管在研究期间每个十年观察到死亡率的改善，但 HCM 的死亡风险仍然高于预期。
